BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial In Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
Wed, 17 Jan 2007 08:00 AM EST
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has initiated a pivotal trial of its lead oncology drug, Fodosine(TM), in the treatment of patients with relapsed or refractory T-cell leukemia/lymphoma. [click link for full article] ...
Related Topics
- Clinical Trials
- Leukemia
- Lymphoma
- Leukemia, Childhood
- Childhood Leukemia
- Adult Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, Childhood
- Leukemia, Acute Lymphoblastic, Adult
- Leukemia, Acute Lymphoblastic, Childhood
- Childhood Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Leukemia, Adult Acute
- Chronic Lymphocytic Leukemia
- Leukemia, Chronic Lymphocytic
- Pharmacology
- Burkitt's Lymphoma
- Lymphoma, Burkitt's
- Trastuzumab
- Psychopharmacology

Not Signed In -

